赛诺菲的药物amlitelimab在治疗青少年和成年人中度过重症湿疹方面表现出强的结果, 症状减少, 安全性良好. Sanofi's drug amlitelimab shows strong results in treating moderate to severe eczema in teens and adults, with reduced symptoms and good safety.

赛诺菲报告了两项晚期试验的积极结果,显示其实验药物amlitelimab有效治疗12周或以上的患者中度至重度湿疹,每四周或12周有所改善. Sanofi reports positive results from two late-stage trials showing its experimental drug amlitelimab effectively treats moderate to severe eczema in patients 12 and older over 24 weeks, with benefits seen every four or 12 weeks. 药物减少了,干燥和炎症等症状,并且耐受性良好,安全性不变. The drug reduced symptoms like itching, dryness, and inflammation, and was well-tolerated with a consistent safety profile. 根据研究结果,Sanofi计划为治疗工作提交全球监管文件。 Based on the findings, Sanofi plans global regulatory submissions for the treatment.